To compare expression of IDO1 in tumor endothelial cells to that of tumor-infiltrating leukocytes, B16-F10 tumor bearing mice were treated with agonistic CD40 mAb or isotype control and CD45−CD31+ endothelial cells and CD45+ leukocytes were isolated using FACS before the start of therapy (day 12), one day after the last treatment (day 16) and four days after the last treatment (day 19). This evidence concerns the gene PTPRC and neoplasm.